Drugs / Insulin glargine/lixisenatide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02752828 | May 2016 → Mar 2018 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-06-28 | Sanofi | Results Media Update: New Soliqua®* data shows improved blood sugar control without weight gain versus premixed insulin sanofi.com ↗
The study met both primary endpoints with Soliqua demonstrating noninferiority of blood sugar (HbA 1c ) reduction and superiority on body weight change from baseline compared to premixed insulin. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-28 | Sanofi | Media Update: New Soliqua®* data shows improved blood sugar control without weight gain versus premixed insulin sanofi.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin glargine/lixisenatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02752828 ↗ |
| Known as | iGlarLixi | “Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral...” PMID 32291880 ↗ Sep 2020 |
| Route | Subcutaneous | “Route of administration: subcutaneous” NCT02752828 ↗ |